Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that the company will host a conference call and live audio webcast to report its fourth quarter and year ended 2013 financial results and provide a corporate update on February 26, 2014, at 9:00 AM EST.
To participate by teleconference, please dial (877) 312-5848 (domestic) or (253) 237-1155 (international) and refer to the Acceleron Q4 Earnings Call. To access the live webcast, please select “Events & Presentations” in the Investors & Media section on the Company’s website ( www.acceleronpharma.com). To ensure a timely connection, it is recommended that users register at least 15 minutes before the scheduled webcast.
A replay of the webcast will be archived on the Company’s website and available beginning approximately two hours after the event.
About AcceleronAcceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases. For more information, please visit www.acceleronpharma.com.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts